Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

Show other versions (1)

The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), eithe...

Full description

Bibliographic Details
Main Authors:	Fernandez-Rozadilla, C, Cazier, J, Moreno, V, Crous-Bou, M, Guinó, E, Durán, G, Lamas, M, López, R, Candamio, S, Gallardo, E, Paré, L, Baiget, M, Páez, D, López-Fernández, L, Cortejoso, L, García, M, Bujanda, L, González, D, Gonzalo, V, Rodrigo, L, Reñé, J, Jover, R, Brea-Fernández, A, Andreu, M, Bessa, X
Format:	Journal article
Language:	English
Published:	2013

Similar Items

Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.
by: Fernandez-Rozadilla, C, et al.
Published: (2013)

A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer
by: Fernandez-Rozadilla, C, et al.
Published: (2014)

A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer.
by: Fernandez-Rozadilla, C, et al.
Published: (2014)

A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12.
by: Fernandez-Rozadilla, C, et al.
Published: (2013)

BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern European populations.
by: Fernandez-Rozadilla, C, et al.
Published: (2013)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
by: Bai L, et al.
Published: (2019-12-01)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
by: Huang Che-Jen, et al.
Published: (2008-11-01)

Analysis of capecitabine plus oxaliplatin (xelox) combination in the management of metastatic colorectal cancer compare with fluorouracil and oxaliplatin combination (folfox)
by: Isnatin Miladiyah
Published: (2016-12-01)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
by: Vincenza Conteduca, et al.
Published: (2018-12-01)

FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study
by: Satoshi Kobayashi, et al.
Published: (2023-02-01)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
by: Touroutoglou Nikolaos, et al.
Published: (2007-05-01)

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
by: Hecht JR, et al.
Published: (2015-06-01)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
by: Keisuke Okuno, et al.
Published: (2023-01-01)

Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy
by: Julia Sánchez-Gundín, et al.
Published: (2019-03-01)

A Rare Case of Severe Lactic Acidosis from 5-Fluorouracil after mFOLFOX6 Treatment in a Patient with Advanced Gastric Cancer
by: Tae Hoon Lee, et al.
Published: (2021-03-01)

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma
by: Huang J, et al.
Published: (2021-11-01)

Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim
by: Hashim, Hazwanie
Published: (2012)

Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications
by: Candice Baldeo, et al.
Published: (2018-06-01)

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy
by: Taku Naiki, et al.
Published: (2017-11-01)

Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy
by: Cazzola M, et al.
Published: (2020-08-01)

Encircling the regions of the pharmacogenomic landscape that determine drug response
by: Adrià Fernández-Torras, et al.
Published: (2019-03-01)

Intention to analyze in pharmacogenomics studies.
by: Gwinn, M, et al.
Published: (2008)

Optimizing pharmacogenomic decision-making by data science
by: Amir M. Behdani, et al.
Published: (2024-02-01)

Optimizing pharmacogenomic decision-making by data science.
by: Amir M Behdani, et al.
Published: (2024-02-01)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
by: Takuo Yamai, et al.
Published: (2022-04-01)

Foot drop - an uncommon presentation of FOLFOX toxicity
by: Tânia Madureira, et al.
Published: (2022-08-01)

Folfox encephalopathy: A rare case series
by: Ullas Batra, et al.
Published: (2017-01-01)

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.
by: Clint Mizzi, et al.
Published: (2017-01-01)

Mouse skeletal muscle adaptations to different durations of treadmill exercise after the cessation of FOLFOX chemotherapy
by: Jessica L. Halle, et al.
Published: (2023-11-01)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
by: Abdosaleh Jafari, et al.
Published: (2023-05-01)

Assessing pharmacogenomic literacy in China through validation of the Chinese version of the Minnesota Assessment of Pharmacogenomic Literacy
by: Lusi Zhang, et al.
Published: (2023-11-01)

Clinical Significance of has_circ_0055625 in Colon Cancer Patients Undergoing FOLFOX Chemotherapy Treatment
by: Liu X, et al.
Published: (2021-01-01)

Pharmacogenomics /
by: Kalow, Werner, et al.
Published: (2005)

Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer
by: C. Fernández-Rozadilla, et al.
Published: (2021-05-01)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
by: Erin D. Powell, et al.
Published: (2009-07-01)

Integrative Gene Set Analysis: Application to Platinum Pharmacogenomics
by: Fridley, Brooke L., et al.
Published: (2017)

Perceptions and Attitudes of Pharmacogenomics Through the Lens of Community Pharmacists and Patients
by: Dalga D. Surofchy, et al.
Published: (2021-05-01)

Clinical Significance of MMP7 Levels in Colorectal Cancer Patients Receiving FOLFOX4 Chemotherapy Treatment
by: Zhou Y, et al.
Published: (2023-06-01)

The role of genetics in pre-eclampsia and potential pharmacogenomic interventions
by: Williams PJ, et al.
Published: (2012-01-01)

Emerging strategies and applications of pharmacogenomics
by: Milos Patrice M, et al.
Published: (2004-11-01)